The Latest Breaking News from Eli Lilly

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Their strong fundamentals, brand strength, and drive to succeed could propel their stock higher.

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, rising R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks, Eli Lilly (LLY), Bristol-Myers (BMY), and Merck & Co. (MRK), which look poised for blockbuster…

As the stock market evolves, leading S&P 500 stocks like Eli Lilly and Company (LLY), Howmet Aerospace (HWM), and NetApp (NTAP) are well-positioned to capitalize on current market conditions and climb higher. Read on….

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

In a recent episode of CNBC's Mad Money show, Jim Cramer named companies like Eli Lilly, Tesla, JPMorgan, and Walmart that could reach a $1 trillion market valuation.

Coca-Cola, Delta, Eli Lilly, Toyota, Visa, Xfinity get ‘brought to you by’ mentions

As Eli Lilly gears up to release its second-quarter earnings next month, analysts project a double-digit bottom-line growth.

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’